Business Context and Reporting Period
This Form 8-K Current Report was filed by Signal Genetics, Inc. on August 18, 2014. The filing discloses the entry into a material definitive agreement regarding the company's corporate headquarters. Note: The request metadata references "Viridian Therapeutics, Inc.", but the filing text explicitly identifies the registrant as Signal Genetics, Inc.
Key Financial Metrics and Obligations
The filing details a new direct financial obligation arising from an office lease:
- Lease Term: 36 months, commencing on or about October 1, 2014.
- Monthly Base Rent: Approximately $13,900.
- Rent Escalation: Increases at a rate of 3% annually.
- Abatement: Three months of rent abatement during the first year.
- Renewal Option: Option to renew for one additional 36-month period.
- Space Size: Approximately 5,560 square feet.
The filing text does not provide values for revenue, profit, cash flow, margins, or existing debt levels.
Material Changes
The primary material change is the relocation of the company's corporate headquarters from New York, New York, to Carlsbad, California. This move replaces the current headquarters with the newly leased space in Carlsbad.
Outlook, Risks, and Contingencies
The filing incorporates the lease terms by reference into Item 2.03 regarding the creation of a direct financial obligation. The document states that the description provided is brief and qualified in its entirety by the full Lease agreement, which will be filed as an exhibit to the Quarterly Report on Form 10-Q for the period ending September 30, 2014. No specific risks or contingencies beyond the standard lease obligations are detailed in this text.
Investor Verification Checklist
- Verify the full text of the Office Building Lease exhibit in the upcoming Form 10-Q for the period ending September 30, 2014.
- Confirm the exact commencement date of the lease (stated as "on or about October 1, 2014").
- Review the company's cash position to ensure liquidity is sufficient to cover the new monthly rent obligation of approximately $13,900.
- Clarify the discrepancy between the request metadata (Viridian Therapeutics) and the filing registrant (Signal Genetics).